Dr. Gustavo Ferrer, President of Aventura Pulmonary Institute, joins Yahoo Finance Live to discuss the latest on the coronavirus pandemic.
A sign there could be a buyout offer on the table sent this volatile biotech stock through the roof today.
Moderna (NASDAQ: MRNA) delivered one piece of bad news to investors a few months ago: Chief medical officer (CMO) Tal Zaks will depart in September. The news came during the initial rollout of Moderna's very first product: its coronavirus vaccine. Moderna allayed investor fears this week, however.